Thought Leader
Agilent Technologies and the Agilent Foundation have announced that Professor Pauline Rudd has received an Agilent Thought Leader Award in support of her emerging glycomics research.
Agilent Technologies and the Agilent Foundation have announced that Professor Pauline Rudd has received an Agilent Thought Leader Award in support of her emerging glycomics research. The award includes a grant of funding and instruments to the National Institute for Bioprocessing Research and Training (NIBRT) in Dublin, Ireland. According to the company, the goals of the research are to develop novel approaches to analyse protein glycosylation, which will assist in the characterization of recombinant protein drugs, and to study potential glycan biomarkers associated with disease using liquid chromatography–mass spectrometry.
Maurice N. Treacy, CEO of NIRBT says that the partnership “will focus on multidimensional nanoscale LC–MS–MS separations for the comprehensive analysis of released oligosaccharides.” According to Treacy, combining the two groups’ expertise will “allow the development of novel technologies and complete solutions for rapid glycan analysis for use by the bio-pharmaceutical sector and in academia.”
This is the first award from the company’s new Thought Leader programme, which is reported to promote fundamental advances in the life sciences by contributing financial support, products and/or expertise to the research of influential thought leaders.
For further information please refer to www.nibrt.ie and www.agilent.com.
This story originally appeared in The Column. Click here to view that issue.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
